These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16049637)

  • 1. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.
    Stefanova E; Wall A; Almkvist O; Nilsson A; Forsberg A; Långström B; Nordberg A
    J Neural Transm (Vienna); 2006 Feb; 113(2):205-18. PubMed ID: 16049637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
    Nobili F; Koulibaly M; Vitali P; Migneco O; Mariani G; Ebmeier K; Pupi A; Robert PH; Rodriguez G; Darcourt J
    J Nucl Med; 2002 Aug; 43(8):983-90. PubMed ID: 12163621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
    Potkin SG; Anand R; Fleming K; Alva G; Keator D; Carreon D; Messina J; Wu JC; Hartman R; Fallon JH
    Int J Neuropsychopharmacol; 2001 Sep; 4(3):223-30. PubMed ID: 11602028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
    Stefanova E; Blennow K; Almkvist O; Hellström-Lindahl E; Nordberg A
    Neurosci Lett; 2003 Feb; 338(2):159-63. PubMed ID: 12566177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease.
    Venneri A; Shanks MF; Staff RT; Pestell SJ; Forbes KE; Gemmell HG; Murray AD
    Neuroreport; 2002 Jan; 13(1):83-7. PubMed ID: 11924899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurophysiological predictors of long term response to AChE inhibitors in AD patients.
    Di Lazzaro V; Oliviero A; Pilato F; Saturno E; Dileone M; Marra C; Ghirlanda S; Ranieri F; Gainotti G; Tonali P
    J Neurol Neurosurg Psychiatry; 2005 Aug; 76(8):1064-9. PubMed ID: 16024879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project.
    Ishii H; Ishikawa H; Meguro K; Tashiro M; Yamaguchi S
    Int Psychogeriatr; 2009 Feb; 21(1):148-56. PubMed ID: 19040787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
    Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
    Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
    Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
    Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease.
    Förster S; Buschert VC; Buchholz HG; Teipel SJ; Friese U; Zach C; la Fougere C; Rominger A; Drzezga A; Hampel H; Bartenstein P; Buerger K
    J Alzheimers Dis; 2011; 25(4):695-706. PubMed ID: 21498904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of mental deterioration with the Cognitive Abilities Screening Instrument (CASI) and glucose hypometabolism in Alzheimer's disease: the Osaki-Tajiri Project.
    Yamaguchi S; Meguro K; Ishii H; Meguro M; Akanuma K
    J Clin Neurosci; 2009 Nov; 16(11):1430-4. PubMed ID: 19632119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease.
    Cerci SS; Tamam Y; Kaya H; Yildiz M; Arslan S
    Adv Ther; 2007; 24(3):611-21. PubMed ID: 17660172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.
    Hunt A; Schönknecht P; Henze M; Seidl U; Haberkorn U; Schröder J
    Psychiatry Res; 2007 Jul; 155(2):147-54. PubMed ID: 17524628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of the open multicenter prospective study of safety and tolerability of rivastigmine (exelon) in different titration regimes in mild and moderate Alzheimer's disease].
    Litvinenko IV; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7):29-35. PubMed ID: 19672235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.